Codexis Inc.
CDXS
Get informed when a big investor buys or sells
+ FollowMarket Cap$140.17M
Close$
$-2.83
321.3% downside
Current Fair Value
321.3% downsideOvervalued by 321.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $140.17 Million |
|---|---|
| Enterprise Value | $186.44 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.5 |
| Beta | 2.55 |
| Outstanding Shares | 91,053,000 |
Return
| Return on Equity | -93.22% |
|---|---|
| Return on Assets | -25.59% |
| Return on Invested Capital | -28.22% |
Valuation & Multiples
| P/E Ratio | -3.81 |
|---|---|
| PEG | 39.92 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2.4 |
| Enterprise Value to EBIT | -6.84 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.39 |
| Debt to Equity | 2.23 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.17
Average shareholder expectationRevenue Estimate
$13.82 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.09
Average shareholder expectationRevenue Estimate
$18.92 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.03%▼ 71.48% |
|---|---|
| Total Invested | $40,310▼ 99.97% |
| Investors Holding | 1▼ 150.00% |
ESG Score
No data
About Codexis Inc.
146 employees
CEO: Alison Moore Codexis, Inc. specializes in the invention, advancement, and commercialization of enzymes and various other proteins. Their diverse portfolio encompasses biocatalyst solutions, chemical intermediates designed for subsequent processing, a...